Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Inclusion criteria

• Healthy male volunteers
• Subjects aged 18 - 45 years
• Subjects weighing ≥ 50.0 kg and ≤ 100.0 kg
• Subjects with a body mass index (BMI) ≥ 19.0 and ≤ 26.0 kg/m2

Exclusion criteria

• Subjects with evidence or history of clinically significant disease
• Subjects with a history of previous cancer
• Subjects with a history of hypertension, or abnormal blood pressure at screening/baseline measurements (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg confirmed by a repeat measurement on the same day)
• Subjects with a history of blood donation 3 months before study drug infusion
• Subjects with a history of exposure to antibodies 12 months before study drug infusion
• Subjects with previous exposure to anti-VEGF therapy